>>> Basilea - Reports that U.S. FDA sets date of Advisory Committee meeting on i

Reports that U.S. FDA sets date of Advisory Committee meeting on isavuconazole NDA for the treatment of invasive aspergillosis and mucormycosis for Jan 22nd

Reports today that the U.S. Food and Drug Administration (FDA) announced a public meeting of the Anti

-Infective Drugs Advisory Committee to discuss the New Drug Application (NDA) for the investigational antifungal isavuconazole, which was submitted by a subsidiary of Basilea's licensing partner Astellas Pharma Inc. The meeting is scheduled for Thursday, January 22, 2015.